These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 30982934)
1. Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT Breast Cancer Res Treat; 2019 Jul; 176(1):251. PubMed ID: 30982934 [TBL] [Abstract][Full Text] [Related]
2. Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10 Woodward WA; Cristofanilli M; Merajver SD; Van Laere S; Pusztai L; Bertucci F; Berditchevski F; Polyak K; Overmoyer B; Devi GR; Sterneck E; Schneider R; Debeb BG; Wang X; van Golen KL; El-Zein R; Rahal OM; Alexander A; Reuben JM; Krishnamurthy S; Lucci A; Ueno NT J Cancer; 2017; 8(17):3607-3614. PubMed ID: 29667990 [TBL] [Abstract][Full Text] [Related]
3. Author Correction: Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Deribe YL; Sun Y; Terranova C; Khan F; Martinez-Ledesma J; Gay J; Gao G; Mullinax RA; Khor T; Feng N; Lin YH; Wu CC; Reyes C; Peng Q; Robinson F; Inoue A; Kochat V; Liu CG; Asara JM; Moran C; Muller F; Wang J; Fang B; Papadimitrakopoulou V; Wistuba II; Rai K; Marszalek J; Futreal PA Nat Med; 2018 Oct; 24(10):1627. PubMed ID: 30104769 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species. Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359 [TBL] [Abstract][Full Text] [Related]
5. Correction to: Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants. Yang L; Zhang X; Wang L; Yin S; Zhu B; Xie L; Duan Q; Hu H; Zheng R; Wei Y; Peng L; Han H; Zhang J; Qiu W; Geng H; Siwko S; Zhang X; Liu M; Li D Protein Cell; 2019 Sep; 10(9):700. PubMed ID: 31087276 [TBL] [Abstract][Full Text] [Related]
6. Correction to: Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer. Isnaldi E; Ferraioli D; Ferrando L; Brohée S; Ferrando F; Fregatti P; Bedognetti D; Ballestrero A; Zoppoli G Breast Cancer Res Treat; 2019 Oct; 177(3):773. PubMed ID: 31300923 [TBL] [Abstract][Full Text] [Related]
7. Correction to: Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer. Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM Breast Cancer Res Treat; 2020 Apr; 180(3):623. PubMed ID: 32180072 [TBL] [Abstract][Full Text] [Related]
8. Correction to: 3D-printed spine surgery implants: a systematic review of the efficacy and clinical safety profile of patient-specific and off-the-shelf devices. Burnard JL; Parr WCH; Choy WJ; Walsh WR; Mobbs RJ Eur Spine J; 2020 Jul; 29(7):1786. PubMed ID: 32458078 [TBL] [Abstract][Full Text] [Related]
9. MD Anderson's Population Health Approaches to Cancer Prevention. Foxhall L; Moreno M; Hawk E Tex Med; 2018 Feb; 114(2):34-41. PubMed ID: 29393960 [TBL] [Abstract][Full Text] [Related]
10. PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling. Qin H; Liu X; Li F; Miao L; Li T; Xu B; An X; Muth A; Thompson PR; Coonrod SA; Zhang X Cancer Lett; 2017 Nov; 409():30-41. PubMed ID: 28844713 [TBL] [Abstract][Full Text] [Related]
11. The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations. Zhang W; Borthakur G; Gao C; Chen Y; Mu H; Ruvolo VR; Nomoto K; Zhao N; Konopleva M; Andreeff M Cancer Res; 2016 Mar; 76(6):1528-37. PubMed ID: 26822154 [TBL] [Abstract][Full Text] [Related]
12. Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study. Mery B; Rowinski E; Vallard A; Jacquin JP; Simoens X; Magné N; Doucey P Oncology; 2019; 97(1):1-6. PubMed ID: 30939479 [TBL] [Abstract][Full Text] [Related]
13. Correction: Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study. Clin Cancer Res; 2015 Jul; 21(13):3096. PubMed ID: 26133779 [TBL] [Abstract][Full Text] [Related]
14. Correction to: Long-term results after stapled hemorrhoidopexy: a survey study with mean follow-up of 12 years. Sturiale A; Fabiani B; Menconi C; Cafaro D; Fusco F; Bellio G; Schiano di Visconte M; Naldini G Tech Coloproctol; 2018 Sep; 22(9):733. PubMed ID: 30311025 [TBL] [Abstract][Full Text] [Related]
15. Correction to: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort. Cheng AS; Leung SCY; Gao D; Burugu S; Anurag M; Ellis MJ; Nielsen TO Breast Cancer Res Treat; 2020 Aug; 182(3):765. PubMed ID: 32564259 [TBL] [Abstract][Full Text] [Related]
16. Correction to: Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer. Tresoldi AS; Sburlati LF; Rodari M; Schinkelshoek MS; Perrino M; De Leo S; Montefusco L; Colombo P; Arosio M; Lania AGA; Fugazzola L; Chiti A J Endocrinol Invest; 2018 Aug; 41(8):1017. PubMed ID: 29611050 [TBL] [Abstract][Full Text] [Related]
17. Correction to: Accuracy of genomic selection to predict maize single-crosses obtained through different mating designs. Fritsche-Neto R; Akdemir D; Jannink JL Theor Appl Genet; 2018 Jul; 131(7):1603. PubMed ID: 29796770 [TBL] [Abstract][Full Text] [Related]
18. Correction to: Osteogenic prospective of deriving human dental stem cells in collagen matrix boost. Fang TJ; Wang DH; Wang CY; Poongodi R; Liou NH; Liu JC; Hsu ML; Hong PD; Yang SF; Liu ML J Mater Sci Mater Med; 2018 Jun; 29(7):100. PubMed ID: 29946882 [TBL] [Abstract][Full Text] [Related]
19. E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities. Goto M; Chow J; Muramoto K; Chiba K; Yamamoto S; Fujita M; Obaishi H; Tai K; Mizui Y; Tanaka I; Young D; Yang H; Wang YJ; Shirota H; Gusovsky F J Pharmacol Exp Ther; 2009 Nov; 331(2):485-95. PubMed ID: 19684251 [TBL] [Abstract][Full Text] [Related]
20. Correction to: Gas-phase reaction of benzo[a]anthracene with hydroxyl radical in the atmosphere: products, oxidation mechanism, and kinetics. Dang J; Zhang Q J Mol Model; 2019 Feb; 25(2):53. PubMed ID: 30712174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]